glyceryl trioleate

PreclinicalSmall molecule

FFDA Office of Orphan Products Development

glyceryl trioleate is one of 7 small molecule programs targeting Adrenoleukodystrophy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdrenoleukodystrophyActive, not recruiting

AdrenoleukodystrophyPreclinical

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Adrenoleukodystrophy

#DrugCompanyPhaseTrials

Mirapex

Boehringer Ingelheim

Approved

1 2

Cytoxan

BBaxter Healthcare Corporation

Busulfex

Thalomid

1 5

DUOC-01

JJoanne Kurtzberg, MD

Phase 1

1 6

Interferon-Beta

Biogen

Preclinical

1 7

glyceryl trioleate

FFDA Office of Orphan Products Development

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Adrenoleukodystrophy1 trial

Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy

Completed·FFDA Office of Orphan Products Development·N/A·NCT00004450·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for glyceryl trioleate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — glyceryl trioleate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for glyceryl trioleate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — FDA Office of Orphan Products Development company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: FFDA Office of Orphan Products Development

glyceryl trioleate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Adrenoleukodystrophy1 trial

References

Drug Info

Quick Facts

Related News